Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Cellectar Biosciences, Inc./ 10-Q

Quarterly Report · 10-Q

Cellectar Biosciences, Inc.

CLRBNASDAQEQUITYCurrent

Quarterly Report

Filed May 14, 2026Accepted May 14, 2026, 7:00 AM EDTCIK 1279704Accession 0001104659-26-060678
View company →Permanent SEC source ↗
Share

Company context

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.

Current securities

CLRBNASDAQ · EQUITY · Current
Historical securities (2)
CLRBWNASDAQ · WARRANT · Historical · closed Aug 21, 2019CLRBZNASDAQ · WARRANT · Historical · closed Apr 16, 2021

Recent company filings

  1. Results of Operations and Financial ConditionNov 10, 2026
  2. 10-Q filingNov 10, 2026
  3. SCHEDULE 13G - filed by Caligan Partners LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
  4. SCHEDULE 13G - filed by STEMPOINT CAPITAL LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
  5. SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Cellectar Biosciences, Inc.Aug 14, 2026

Registered securities in this filing

Cellectar Biosciences, Inc. · 10-Q · Filed 2026-05-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.00001

Symbol
CLRB
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Duration_1_1_2026_To_3_31_2026_jjbL45f700-RphOwIIQeTQ

Dimensions: Not supplied

Accession 000110465926060678 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.